Ziel
We have identified a novel family of potent small molecule activators of the NLRP3 inflammasome. The goal of this project is to determine the feasibility of developing these new immunostimulators into an attractive commercial proposition. Establishment of technical feasibility will involve identification the most promising modifications of our drug candidates and testing their efficacy in disease models of cancer and immunization. In addition, we will determine commercial feasibility by conducting market research and competition analysis and by engaging potential industry partners.
Wissenschaftliches Gebiet
Schlüsselbegriffe
Programm/Programme
Finanzierungsplan
ERC-POC - Proof of Concept GrantGastgebende Einrichtung
UNIVERSITAETSKLINIKUM FREIBURG
Netto-EU-Beitrag
€ 150 000,00
Adresse
HUGSTETTER STRASSE 49
79106 Freiburg
Deutschland
79106 Freiburg
Deutschland
Region
Baden-Württemberg
Freiburg
Freiburg im Breisgau, Stadtkreis
Aktivitätstyp
Higher or Secondary Education Establishments
Links
Gesamtkosten
Keine Daten